| Dr Vipra Sharma, MD | |
|
300 Kensington Ave, New Britain, CT 06051-3916 | |
| (860) 224-6254 | |
| Not Available |
| Full Name | Dr Vipra Sharma |
|---|---|
| Gender | Female |
| Speciality | Hematology/oncology |
| Experience | 19 Years |
| Location | 300 Kensington Ave, New Britain, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679760615 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 051080 (Connecticut) | Primary |
| 207R00000X | Internal Medicine | 051080 (Connecticut) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St. Vincent's Medical Center | Bridgeport, CT | Hospital |
| Hartford Hospital | Hartford, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hartford Healthcare Medical Group Specialists Pllc | 3173866241 | 1138 |
| Svmc Holdings, Inc | 5294066874 | 6 |
News Archive
Cell Therapeutics, Inc. announced the preliminary results of a phase II study of paclitaxel poliglumex (OPAXIO) combined with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed high-grade gliomas.
EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, today announced that it has entered into definitive agreements to acquire Biochrom AG located in Berlin, Germany.
According to a recent study by the Centers for Disease Control and Prevention, a concussion sends students to the emergency room every five minutes in this country.
Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced it has completed enrollment in its ongoing 200-patient Phase 2b study of AKB-6548 for the treatment of anemia associated with chronic kidney disease (CKD) in patients who are not dependent on dialysis.
› Verified 5 days ago
| Entity Name | Starling Physicians, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467537290 PECOS PAC ID: 7517863749 Enrollment ID: O20031209000877 |
News Archive
Cell Therapeutics, Inc. announced the preliminary results of a phase II study of paclitaxel poliglumex (OPAXIO) combined with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed high-grade gliomas.
EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, today announced that it has entered into definitive agreements to acquire Biochrom AG located in Berlin, Germany.
According to a recent study by the Centers for Disease Control and Prevention, a concussion sends students to the emergency room every five minutes in this country.
Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced it has completed enrollment in its ongoing 200-patient Phase 2b study of AKB-6548 for the treatment of anemia associated with chronic kidney disease (CKD) in patients who are not dependent on dialysis.
› Verified 5 days ago
| Entity Name | St. Vincent's Multispecialty Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043544489 PECOS PAC ID: 6204977218 Enrollment ID: O20100112000538 |
News Archive
Cell Therapeutics, Inc. announced the preliminary results of a phase II study of paclitaxel poliglumex (OPAXIO) combined with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed high-grade gliomas.
EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, today announced that it has entered into definitive agreements to acquire Biochrom AG located in Berlin, Germany.
According to a recent study by the Centers for Disease Control and Prevention, a concussion sends students to the emergency room every five minutes in this country.
Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced it has completed enrollment in its ongoing 200-patient Phase 2b study of AKB-6548 for the treatment of anemia associated with chronic kidney disease (CKD) in patients who are not dependent on dialysis.
› Verified 5 days ago
| Entity Name | Hartford Healthcare Medical Group Specialists Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023584216 PECOS PAC ID: 3173866241 Enrollment ID: O20190514001441 |
News Archive
Cell Therapeutics, Inc. announced the preliminary results of a phase II study of paclitaxel poliglumex (OPAXIO) combined with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed high-grade gliomas.
EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, today announced that it has entered into definitive agreements to acquire Biochrom AG located in Berlin, Germany.
According to a recent study by the Centers for Disease Control and Prevention, a concussion sends students to the emergency room every five minutes in this country.
Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced it has completed enrollment in its ongoing 200-patient Phase 2b study of AKB-6548 for the treatment of anemia associated with chronic kidney disease (CKD) in patients who are not dependent on dialysis.
› Verified 5 days ago
| Entity Name | Svmc Holdings, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942224696 PECOS PAC ID: 5294066874 Enrollment ID: O20211116000531 |
News Archive
Cell Therapeutics, Inc. announced the preliminary results of a phase II study of paclitaxel poliglumex (OPAXIO) combined with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed high-grade gliomas.
EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, today announced that it has entered into definitive agreements to acquire Biochrom AG located in Berlin, Germany.
According to a recent study by the Centers for Disease Control and Prevention, a concussion sends students to the emergency room every five minutes in this country.
Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced it has completed enrollment in its ongoing 200-patient Phase 2b study of AKB-6548 for the treatment of anemia associated with chronic kidney disease (CKD) in patients who are not dependent on dialysis.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Vipra Sharma, MD 300 Kensington Ave, New Britain, CT 06051-3916 Ph: (860) 224-6254 | Dr Vipra Sharma, MD 300 Kensington Ave, New Britain, CT 06051-3916 Ph: (860) 224-6254 |
News Archive
Cell Therapeutics, Inc. announced the preliminary results of a phase II study of paclitaxel poliglumex (OPAXIO) combined with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed high-grade gliomas.
EMD Millipore, the Life Science division of Merck KGaA of Darmstadt, Germany, today announced that it has entered into definitive agreements to acquire Biochrom AG located in Berlin, Germany.
According to a recent study by the Centers for Disease Control and Prevention, a concussion sends students to the emergency room every five minutes in this country.
Akebia Therapeutics, Inc., a biopharmaceutical company focused on the development of novel proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced it has completed enrollment in its ongoing 200-patient Phase 2b study of AKB-6548 for the treatment of anemia associated with chronic kidney disease (CKD) in patients who are not dependent on dialysis.
› Verified 5 days ago
Dr. Michael G. Genovesi, M.D. Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 300 Kensington Ave, New Britain, CT 06051 Phone: 860-224-6266 Fax: 860-224-6269 | |
Brenda Nurse, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 2150 Corbin Ave, New Britain, CT 06053 Phone: 860-832-6248 | |
Dr. Yousong Wang, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 300 Kensington Ave, New Britain, CT 06051 Phone: 860-612-0485 | |
Justin B Lundbye, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 100 Grand St, Cardiology Department, New Britain, CT 06052 Phone: 860-224-5731 Fax: 860-224-5749 | |
Rekha Kumari, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 100 Grand St, New Britain, CT 06052 Phone: 860-224-5990 Fax: 860-972-7040 | |
Dr. Manmeet Kaur, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 100 Grand St, Joslin Diabetes Center, New Britain, CT 06052 Phone: 860-224-5672 | |
Dr. Ujwol Karmacharya, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 100 Grand Street, New Britain, CT 06052 Phone: 860-224-5011 |